Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.

Jacob N HunnicuttJolyon Fairburn-BeechMary Elizabeth GeorgiouAnna RichardsYun Irene GreganHolly A QuasnyDeven Chauhan

Published in: Lupus science & medicine (2022)

Improved disease control and reduced glucocorticoid use was achieved for a proportion of patients following up to 12 months of belimumab treatment in a US real-world setting.

Keyphrases

systemic lupus erythematosus
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
disease activity
peritoneal dialysis
combination therapy
smoking cessation